An official website of the United States government
The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before
sharing sensitive information, make sure you’re on a federal
government site.
The site is secure.
The https:// ensures that you are connecting to the
official website and that any information you provide is encrypted
and transmitted securely.
Erlotinib is a tyrosine kinase receptor inhibitor approved by the US Food and Drug Administration (FDA) for the treatment of non-small cell lung cancer and advanced pancreatic cancer. This drug inhibits the epidermal growth factor receptor (EGFR), affecting both wild-type and mutated EGFRs, which are crucial in cellular differentiation, proliferation, and angiogenesis. Erlotinib’s efficacy is influenced by proper patient selection based on thorough diagnostic evaluation. The drug has a narrow therapeutic index, and its use is associated with adverse effects such as diarrhea and rash.
Azzoli CG, Temin S, Giaccone G. 2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. J Oncol Pract. 2012 Jan;8(1):63-6.
-
PMC
-
PubMed
Bulbul A, Husain H. First-Line Treatment in EGFR Mutant Non-Small Cell Lung Cancer: Is There a Best Option? Front Oncol. 2018;8:94.
-
PMC
-
PubMed
Saito H, Fukuhara T, Furuya N, Watanabe K, Sugawara S, Iwasawa S, Tsunezuka Y, Yamaguchi O, Okada M, Yoshimori K, Nakachi I, Gemma A, Azuma K, Kurimoto F, Tsubata Y, Fujita Y, Nagashima H, Asai G, Watanabe S, Miyazaki M, Hagiwara K, Nukiwa T, Morita S, Kobayashi K, Maemondo M. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol. 2019 May;20(5):625-635.
-
PubMed
Wang Y, Hu GF, Zhang QQ, Tang N, Guo J, Liu LY, Han X, Wang X, Wang ZH. Efficacy and safety of gemcitabine plus erlotinib for locally advanced or metastatic pancreatic cancer: a systematic review and meta-analysis. Drug Des Devel Ther. 2016;10:1961-72.
-
PMC
-
PubMed
Gordon MS, Hussey M, Nagle RB, Lara PN, Mack PC, Dutcher J, Samlowski W, Clark JI, Quinn DI, Pan CX, Crawford D. Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317. J Clin Oncol. 2009 Dec 01;27(34):5788-93.
-
PMC
-
PubMed
